Eli Lilly and Company vs Viridian Therapeutics, Inc.: Strategic Focus on R&D Spending

Eli Lilly vs. Viridian: A Decade of R&D Investment

__timestampEli Lilly and CompanyViridian Therapeutics, Inc.
Wednesday, January 1, 20144733600000293000
Thursday, January 1, 201547964000001002000
Friday, January 1, 20165243900000888000
Sunday, January 1, 2017528180000019623000
Monday, January 1, 2018505120000030421000
Tuesday, January 1, 2019559500000034794000
Wednesday, January 1, 2020608570000028304000
Friday, January 1, 2021702590000056886000
Saturday, January 1, 20227190800000100894000
Sunday, January 1, 20239313400000159765000
Monday, January 1, 202414271000000
Loading chart...

Unlocking the unknown

Strategic R&D Investments: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Eli Lilly and Company has consistently demonstrated its strategic focus on R&D, with expenditures growing by nearly 97% from 2014 to 2023. In contrast, Viridian Therapeutics, Inc., a smaller player, has shown a remarkable increase in R&D spending, skyrocketing by over 54,000% during the same period, albeit from a much smaller base.

Eli Lilly's robust investment, peaking at approximately $9.3 billion in 2023, underscores its dedication to maintaining a competitive edge in the pharmaceutical industry. Meanwhile, Viridian's aggressive R&D growth, reaching around $160 million in 2023, highlights its ambition to innovate and expand its market presence. This juxtaposition of R&D strategies offers a fascinating glimpse into the diverse approaches companies take to drive growth and innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025